Vistagen to Present at Stifel 2024 Virtual CNS Days
Vistagen (VTGN) to participate in Stifel 2024 Virtual CNS Days, presenting groundbreaking therapies for psychiatric and neurological disorders. CEO Shawn Singh to host fireside chat on March 20, 2024.
03/11/2024 - 08:30 AM
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--
Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Virtual CNS Days taking place March 19 to 20, 2024.
Stifel 2024 Virtual CNS Days
Shawn Singh, Chief Executive Officer, will participate in a fireside chat on Wednesday, March 20 at 12:00 p.m. Eastern Time.
A webcast will be accessible through the “Events ” page in the “Investors” section of the Company’s website at www.Vistagen.com . Investors interested in arranging a one-on-one meeting during the conference should contact their Stifel representative.
About Vistagen
Vistagen (Nasdaq: VTGN) is a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders. Five of Vistagen’s clinical-stage neuroscience pipeline candidates belong to a new class of drugs known as pherines, which are investigational neuroactive nasal sprays with innovative proposed mechanisms of action that activate chemosensory neurons in the nasal passages to impact fundamental neural circuitry in the brain without the need for systemic absorption or binding to receptors in the brain. Vistagen’s sixth investigational candidate is an oral prodrug with potential to inhibit, but not block, NMDA receptor activity. At Vistagen, we are passionate about delivering differentiated treatments that set new standards of care for people living with anxiety, depression, and other neurological disorders. Connect at www.Vistagen.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240311902490/en/
Investors:
Mark A. McPartland
(650) 577-3606
markmcp@vistagen.com
Media:
Caren Scannell
(650) 577-3601
cscannell@vistagen.com
Source: Vistagen
When is Stifel 2024 Virtual CNS Days taking place?
Stifel 2024 Virtual CNS Days will be held on March 19 to 20, 2024.
Who will be participating in a fireside chat during the event?
Vistagen's CEO, Shawn Singh, will host a fireside chat on Wednesday, March 20 at 12:00 p.m. Eastern Time.
How can investors access the webcast of the event?
Investors can access the webcast through the 'Events' page in the 'Investors' section of Vistagen's website at www.Vistagen.com.
How can investors arrange a one-on-one meeting during the conference?
Investors interested in arranging a one-on-one meeting should contact their Stifel representative.
What is Vistagen's ticker symbol?
Vistagen's ticker symbol is VTGN.
VistaGen Therapeutics Inc
VTGN Rankings
#3612 Ranked by Stock Gains
VTGN Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
About VTGN
we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.